Prof. Dr. Jack Schalken 
Chief Scientific Officer
Jack Schalken obtained his M.Sc. and Ph.D. in Biochemistry at Radboud UMC in Nijmegen. He holds a professorship in Experimental Urology and is research director at RUMC (Nijmegen, The Netherlands).
He is renowned for his expertise on the molecular basis of (therapy resistant) prostate cancer and is a board member of international scientific organizations including the European Society for Urological Research (ESUR).
Jack is experienced in coordinating large multi-centered prostate cancer research programs. He led the team that developed the PCA3 prostate cancer test and is co-founder/ CSO at Noviogendix, a spin-off company from RUMC, offering molecular diagnostics for GU cancer.